NCT04349358Active, not recruitingPhase 2
18F-Fluorocholine (FCH) versus 18F-Fluorodesoxyglucose (FDG) PET/CT for the detection of lesions in patients with multiple myeloma
Source: EU CTIS (euclinicaltrials.eu) · Last updated 23 Aug 2024
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 38 (estimated)
- First submitted
- 24 Jul 2024
- Start date
- 15 Dec 2020
- Lead sponsor
- Centr Georges Francois Leclerc
- Diseases
- Multiple myeloma
- NCT number
- NCT04349358
- EU CT number
- 2024-516682-36-00
- EudraCT number
- 2019-003627-38
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 38
- 3 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study, not your situation.
Sites (3)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| CHU Besancon Coordinator of this site? Confirm its status | Besancon Cedex | France | Active, not recruiting |
| Centre Hospitalier Universitaire de Dijon Coordinator of this site? Confirm its status | Dijon | France | Active, not recruiting |
| Centr Georges Francois Leclerc Coordinator of this site? Confirm its status | Dijon | France | Active, not recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.